Crysvita Market Report 2026

Crysvita Market Overview

• The Crysvita market growth in the historic period has been driven by limited treatment options for xlh, orphan drug approvals • Market expansion is supported by growth in rare disease screening, expansion of adult xlh treatment • Growth Driver: Rise Of Personalized Medicine Fueling Growth In The Market • Market Trend: Advancements In Prefilled And Patient-Friendly Formulations Enhancing Treatment Convenience And Accessibility • North America was the largest region in 2025.

What Is Covered Under Crysvita Market?

Crysvita is a prescription medication used to treat X-linked hypophosphatemia (XLH), a rare genetic disorder that leads to low levels of phosphate in the blood, resulting in weak bones, bone pain, and other skeletal issues. The main types of crysvita are 10 mg, 20 mg, and 30 mg. CysVita 10 mg is a pharmaceutical product that typically contains cysteine as its active ingredient, often in the form of a cysteine-based supplement. These are used for various patient demographics such as pediatric, and adult. The various disease prevalences include x-linked hypophosphatemia, and tumor-induced osteomalacia and are used for various applications such as hospitals, clinics, and others.

What Is The Crysvita Market Growth Forecast?

The growth in the forecast period can be attributed to growth in rare disease screening, expansion of adult xlh treatment, increased biologic orphan drug investment, broader reimbursement access, improved long term clinical outcomes. Major trends in the forecast period include rising adoption of targeted therapies for rare diseases, growth of precision medicine in genetic disorders, expansion of pediatric rare disease treatments, increased awareness of x linked hypophosphatemia, shift toward long term disease management.

Global Crysvita Market Segmentation

1) By Type: 10 mg, 20 mg, 30 mg 2) By Patient Demographics: Pediatric, Adult 3) By Disease Prevalence: X-Linked Hypophosphatemia, Tumor-Induced Osteomalacia 4) By Application: Hospitals, Clinics, Other Applications

What Is The Driver Of The Crysvita Market?

Rising personalized medicine is expected to propel the growth of the Crysvita market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare strategies to the individual characteristics of each patient, such as their genetic makeup, environment, and lifestyle, to achieve the most effective and precise outcomes. Advances in genomic technologies and better understanding of diseases allow for the development of targeted therapies tailored to individual genetic profiles. This combination is driving the rise of personalized medicine, improving treatment effectiveness and patient outcomes. Crysvita exemplifies personalized medicine by offering targeted treatment for X-linked hypophosphatemia (XLH), addressing the unique genetic and metabolic needs of individual patients to improve bone health and quality of life. For instance, in February 2024, according to a report published by the Personalized Medicine Coalition, a US-based organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, rising personalized medicine drives the crysvita industry.

Key Players In The Global Crysvita Market

Major companies operating in the crysvita market are Kyowa Kirin Co. Ltd., Ultragenyx Pharmaceutical Inc.

Global Crysvita Market Trends and Insights

Major companies operating in the crysvita market are focusing on developing more patient-friendly and prefilled formulations and improving treatment convenience to enhance therapeutic accessibility and outcomes. For instance, in June 2025, Kyowa Kirin Co Ltd., a Japan-based pharmaceytical company, has received approval in Japan for a new prefilled syringe formulation of Crysvita, offering a more convenient and safer alternative to the existing vial version. Originally approved in 2019 and later enabled for self-injection in 2020, Crysvita treats FGF23-related hypophosphatemic conditions such as XLH and TIO. The new syringe format simplifies administration, reduces preparation steps, and eases the burden on patients, families, and healthcare professionals. As the only therapy that directly targets FGF23, Crysvita® continues to play a key role in managing phosphate-regulating disorders. This launch reflects Kyowa Kirin’s ongoing commitment to advancing patient-friendly treatment options.

What Are Latest Mergers And Acquisitions In The Crysvita Market?

In November 2025, OMERS Life Sciences, a Canada-based life sciences-focused investment capital company, acquired a 25% royalty interest in future North American sales of Crysvita from Ultragenyx for $400 million. With this acquisition, OMERS aims to strengthen its portfolio returns by expanding exposure to a high-growth rare-disease therapy with a proven commercial track record. The acquired royalty interest originates from Ultragenyx, a US-based biopharmaceutical company that specializes in innovative treatments for serious rare and ultra-rare genetic diseases.

Regional Insights

North America was the largest region in the crysvita market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Crysvita Market?

The crysvita market consists of sales of injection and drug formulation. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Crysvita Market Report 2026?

The crysvita market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the crysvita industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.